Problems encountered in recruiting patients to an ophthalmic drug trial

Quick, A. M.; Khaw, P. T.; Elkington, A. R.
June 1989
British Journal of Ophthalmology;Jun1989, Vol. 73 Issue 6, p432
Academic Journal
No abstract available.


Related Articles

  • Are we pharmacovigilant enough in ophthalmic practice? Dubey, Ashok; Handu, Shailendra S. // Indian Journal of Ophthalmology;May2013, Vol. 61 Issue 5, p226 

    No drug is absolutely safe. Pharmacovigilance is the science related to detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems. The ocular medications and devices can cause localized and systemic adverse effects. Not all adverse effects...

  • Industry Pipeline.  // Ocular Surgery News;7/25/2010, Vol. 28 Issue 14, p20 

    The article announces several ophthalmic drug trials and approvals.

  • Better compliance possible with combo glaucoma product. Guttman, Cheryl; Schuman, Joel S. // Ophthalmology Times;03/15/2001, Vol. 26 Issue 6, p25 

    Examines the therapeutic use of a combination of ophthalmic drugs for glaucoma patients. Benefits of a combination glaucoma product; Potential for improved safety; Overview of the clinical trials for combination ophthalmic drugs.

  • Time for a quality check before recruiting patients. Holtedahl, Knut A.; Meland, Eivind // BMJ: British Medical Journal (International Edition);7/7/2007, Vol. 335 Issue 7609, p7 

    A letter to the editor is presented discussing quality control in recruiting patients for drug trials.

  • Drugmakers: Optimized for Failure? Goodman, Nat // Pharma DD: Tracking Discovery & Development;Jul/Aug2006, Vol. 1 Issue 1, p16 

    The author expresses his outlook for drug development in the U.S. He highlights problems encountered in clinical trials of drugs such as in their credibility, statistics and short duration of most of the trials. A background on the emergence of clinical trials is offered. He emphasizes the...

  • Does dapsone reduce the need for steroids? Guttman, Cheryl // Dermatology Times;Sep97, Vol. 18 Issue 9, p34 

    Investigates the efficacy of dapsone as a steroid-sparing agent in patients with pemphigus vulgaris. Primary measure of dapsone efficacy; Account on the trials and other outcome variables for dapsone; Problem encountered in evaluating drug therapy on patients with pemphigus vulgaris.

  • Tribulations for clinical trials. Macintyre, I.M.C. // BMJ: British Medical Journal (International Edition);5/11/91, Vol. 302 Issue 6785, p1099 

    Focuses on the problems encountered on clinical trials in Great Britain. Inadequacy on entry of patients; Design of clinical trials; Provisions of trial protocol.

  • Review on Ocular Inserts. Rathore, K. S.; Nema, R. K. // International Journal of PharmTech Research;Apr2009, Vol. 1 Issue 2, p164 

    The conventional dosage forms are account for 90% of currently accessible ophthalmic formulations. The major problem encountered is rapid precornel drug loss. To improve ocular drug bioavailability, there are significant efforts directed towards newer drug delivery systems for ophthalmic...

  • Fixed latanoprost-timolol combination lowers IOP safely. Guttman, Cheryl; Higginbotham, Eve J. // Ophthalmology Times;03/15/2001, Vol. 26 Issue 6, p32 

    Deals with the use of the fixed combination of ophthalmic drugs latanoprost and timolol in patients with primary open-angle glaucoma. Advantages of fixed ophthalmic drugs over the separate use of latanoprost and timolol; Overview of the clinical trials for the fixed combined drugs.

  • Olopatadine 0.2% provides extended efficacy during peak pollen periods. Charters, Lynda // Ophthalmology Times;8/15/2004, Vol. 29 Issue 16, p20 

    Reports on the use of olopatadine hydrochloride ophthalmic solution for patients who wear contact lenses. Mechanism of anti-allergy action; Drug dosage and administration; Results of clinical trials of the drug. INSET: Take-Home Message.


Read the Article


Sign out of this library

Other Topics